All In Biotech

Drug Trial Radar · NCT00303784

Prostate Adenocarcinoma TransCutaneous Hormones

A Randomized-Controlled Trial of Transcutaneous Oestrogen Patches Versus LHRH Agonists in Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Nov 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 2,200 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,200

Planned (sponsor's estimate)

Start

Mar 2006

Primary completion

Aug 2021

Study completion Aug 2021

Sponsor

Lead sponsor
University College, LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medical Research Council
First posted
Mar 17, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: The increasingly prolonged and extended use of androgen deprivation therapy (ADT) in the treatment of prostate cancer, usually achieved through the administration of LHRH agonists, has raised concerns about long-term toxicities, in particular osteoporosis and adverse metabolic changes which may be associated with type II diabetes and increased cardiovascular risk. An alternative approach is to investigate other methods of ADT. Oral oestrogen has been shown to be as effective as LHRH and surgical orchidectomy in achieving castrate levels of testosterone and has equivalent or improved prostate cancer outcomes but is not used routinely as first-line therapy because of the risk of cardiovascular system (CVS) complications. The CVS complications have been attributed to first-pass hepatic metabolism. Administering oestrogen parenterally avoids the entero-hepatic circulation and so is expected to mitigate the risk of CVS toxicity whilst still effectively suppressing testosterone to castrate levels. This hypothesis has been supported by results from the early stages of this trial which have provided sufficient indication of the safety and efficacy of the patches to warrant further investigation of the treatment in this setting, as recommended by the IDMC.. PURPOSE: This randomized phase III trial is studying how well the estrogen skin patch works compared with luteinizing hormone-releasing hormone agonist injections in treating patients with locally advanced or metastatic prostate cancer.

Conditions

  • Anemia
  • Cardiovascular Complications
  • Hot Flashes
  • Osteoporosis
  • Prostate Cancer

Interventions

  • GoserelinDrug

    3.6mg implant, in pre-filled syringe

  • EstradiolDrug

    Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free SurvivalTime frame: Up to 180 months
  2. Overall SurvivalTime frame: Up to 180 months

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Queen's Hospital

    Burton-on-Trent, England, United Kingdom · Recruiting

  • Addenbrooke's Hospital

    Cambridge, England, United Kingdom · Recruiting

  • Walsgrave Hospital

    Coventry, England, United Kingdom · Recruiting

  • Mid Cheshire Hospitals Trust- Leighton Hopsital

    Crewe, England, United Kingdom · Recruiting

  • Mayday University Hospital

    Croydon, England, United Kingdom · Recruiting

  • Derbyshire Royal Infirmary

    Derby, England, United Kingdom · Recruiting

  • Castle Hill Hospital

    East Yorkshire, England, United Kingdom · Recruiting

  • Royal Devon and Exeter Hospital

    Exeter, England, United Kingdom · Recruiting

  • Grantham and District Hospital

    Grantham, Lincolnshire, England, United Kingdom · Recruiting

  • Ipswich Hospital

    Ipswich, England, United Kingdom · Recruiting

  • Kidderminster Hospital

    Kidderminster Worcestershire, England, United Kingdom · Recruiting

  • Leeds Cancer Centre at St. James's University Hospital

    Leeds, England, United Kingdom · Recruiting

  • St. Mary's Hospital

    London, England, United Kingdom · Recruiting

  • Charing Cross Hospital

    London, England, United Kingdom · Recruiting

  • Maidstone Hospital

    Maidstone, England, United Kingdom · Recruiting

  • James Cook University Hospital

    Middlesbrough, England, United Kingdom · Recruiting

  • Nottingham City Hospital

    Nottingham, England, United Kingdom · Recruiting

  • Kings Mill Hospital

    Nottinghamshire, England, United Kingdom · Recruiting

  • George Eliot Hospital

    Nuneaton, England, United Kingdom · Recruiting

  • Alexandra Healthcare NHS

    Redditch, Worcestershire, England, United Kingdom · Recruiting

  • Hope Hospital

    Salford, England, United Kingdom · Recruiting

  • Scarborough General Hospital

    Scarborough, England, United Kingdom · Recruiting

  • Stepping Hill Hospital

    Stockport, England, United Kingdom · Recruiting

  • Hillingdon Hospital

    Uxbridge, England, United Kingdom · Recruiting

  • Walsall Manor Hospital

    Walsall, England, United Kingdom · Recruiting

  • Warwick Hospital

    Warwick, England, United Kingdom · Recruiting

  • Worthing Hospital

    Worthing, England, United Kingdom · Recruiting

  • Yeovil District Hospital

    Yeovil, England, United Kingdom · Recruiting

  • Ayr Hospital

    Ayr, Scotland, United Kingdom · Recruiting

  • Beatson West of Scotland Cancer Centre

    Glasgow, Scotland, United Kingdom · Recruiting

  • Velindre Cancer Center at Velindre Hospital

    Cardiff, Wales, United Kingdom · Recruiting

  • University Hospital of Wales

    Cardiff, Wales, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.